Johnson And Johnson's Suppliers recorded an increase in sales by 9.77 % year on year in Q2 2026, sequentially sales grew by 8.75 %, Johnson And Johnson recorded an increase in cost of sales by 5.55 % year on year, relative to one quarter ago cost of sales fell by -0.68 % in Q2.
Johnson And Johnson's Suppliers recorded an increase in sales by 9.77 % year on year in Q2 2026, sequentially sales grew by 8.75 %, Johnson And Johnson recorded increase in cost of sales by 5.55 % year on year, compare to one quarter ago cost of sales fell by -0.68 % in Q2.
The Company’s raw materials are generally available from multiple sources, and temporary shortages are unlikely to materially affect financial results. Its subsidiaries secure patent protection for their products and processes, holding or licensing numerous patents in the U.S. and internationally. These subsidiaries face patent challenges from third parties seeking to market generic and biosimilar versions of key pharmaceutical products.
The Company’s largest product, DARZALEX and DARZALEX FASPRO, represented approximately 15.0% of total revenues in fiscal 2025. Genmab A/S owns two patent families related to DARZALEX, licensed exclusively to Janssen Biotech, Inc., with royalty rates ranging from 12% to 20% of net sales, totaling about $2.4 billion in 2025. These patents expire in the U.S. in 2029 and in Europe in 2031/2032. Janssen Biotech, Inc. holds separate patent portfolios for DARZALEX FASPRO and DARZALEX IV.
The second largest product, STELARA, accounted for approximately 6.5% of total revenues in fiscal 2025. Third parties have filed for biosimilar approvals globally, which is expected to negatively impact sales. The third largest product, TREMFYA, accounted for about 5.5% of total revenues in fiscal 2025. Janssen Biotech, Inc. owns multiple patent families related to TREMFYA, including a composition patent expiring in the U.S. in 2031, and is party to license agreements with aggregate royalty rates of approximately 5.0% payable to third parties.
The Company’s subsidiaries also protect product trademarks through registrations in the U.S. and other countries. Worldwide sales do not exhibit significant seasonality, although spending is typically higher in the fourth quarter.
Johnson And Johnson's Comment on Supply Chain
The Company’s raw materials are generally available from multiple sources, and temporary shortages are unlikely to materially affect financial results. Its subsidiaries secure patent protection for their products and processes, holding or licensing numerous patents in the U.S. and internationally. These subsidiaries face patent challenges from third parties seeking to market generic and biosimilar versions of key pharmaceutical products.
The Company’s largest product, DARZALEX and DARZALEX FASPRO, represented approximately 15.0% of total revenues in fiscal 2025. Genmab A/S owns two patent families related to DARZALEX, licensed exclusively to Janssen Biotech, Inc., with royalty rates ranging from 12% to 20% of net sales, totaling about $2.4 billion in 2025. These patents expire in the U.S. in 2029 and in Europe in 2031/2032. Janssen Biotech, Inc. holds separate patent portfolios for DARZALEX FASPRO and DARZALEX IV.
The second largest product, STELARA, accounted for approximately 6.5% of total revenues in fiscal 2025. Third parties have filed for biosimilar approvals globally, which is expected to negatively impact sales. The third largest product, TREMFYA, accounted for about 5.5% of total revenues in fiscal 2025. Janssen Biotech, Inc. owns multiple patent families related to TREMFYA, including a composition patent expiring in the U.S. in 2031, and is party to license agreements with aggregate royalty rates of approximately 5.0% payable to third parties.
The Company’s subsidiaries also protect product trademarks through registrations in the U.S. and other countries. Worldwide sales do not exhibit significant seasonality, although spending is typically higher in the fourth quarter.
JNJ's Suppliers Net Income grew by
JNJ's Suppliers Net margin grew in Q2 to
27.08 %
8.75 %
JNJ's Suppliers Net Income grew by 27.08 %
JNJ's Suppliers Net margin grew in Q2 to 8.75 %
Johnson And Johnson's Suppliers Sales Growth
in Q2 2026 by Industry
Sources:
Johnson and Johnson's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Johnson and Johnson’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
3.54 %